Microarrays Are Still a Hit in Drug Discovery as Companies Schedule Third-Quarter Exhibits | GenomeWeb

While the microarray industry is expanding the frontiers of this technology into agriculture, food safety, and even outer space, the platform remains closely linked to the challenges of drug discovery.

And you only have to look at attendance for two third-quarter trade shows — Drug Discovery Technology in Boston starting on Aug. 8, and Chips to Hits on Sept. 20-23, also in Boston — for an illustration (see chart, page 5.)

The two shows are organized by IBC Life Sciences of Westborough, Mass., as part of its drug discovery series.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.